Cyclacel Pharmaceuticals, Inc. (CYCC) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Evoke Pharma, Inc.

Bellerophon Therapeutics, Inc.

Agile Therapeutics, Inc.

Jaguar Health, Inc.

SeqLL, Inc.

TRACON Pharmaceuticals, Inc.

Hoth Therapeutics, Inc.

Cyclacel Pharmaceuticals, Inc.

PainReform Ltd.

CNS Pharmaceuticals, Inc.

Windtree Therapeutics, Inc.

Why is Cyclacel Pharmaceuticals, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Cyclacel Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Cyclacel Pharmaceuticals, Inc.

-98.71%

-0.03

1962.36%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.55%

EBIT Growth (5y)

2.04%

EBIT to Interest (avg)

-18.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.13

Sales to Capital Employed (avg)

0.04

Tax Ratio

31.89%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.81%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.64

EV to EBIT

-0.07

EV to EBITDA

-0.07

EV to Capital Employed

0.21

EV to Sales

0.67

PEG Ratio

Dividend Yield

42.03%

ROCE (Latest)

-281.49%

ROE (Latest)

-97.67%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company

NET SALES(HY)

At USD 0.08 MM has Grown at 478.57%

OPERATING CASH FLOW(Y)

Highest at USD -6.1 MM

NET PROFIT(HY)

Higher at USD -3.8 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 0.1 times

OPERATING PROFIT(Q)

Highest at USD -0.99 MM

-5What is not working for the Company

NET PROFIT(Q)

At USD -2.48 MM has Fallen at -54.98%

RAW MATERIAL COST(Y)

Grown by 77.54% (YoY

CASH AND EQV(HY)

Lowest at USD 8.11 MM

Here's what is working for Cyclacel Pharmaceuticals, Inc.

Net Sales

At USD 0.08 MM has Grown at 478.57%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD -6.1 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD -0.99 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Inventory Turnover Ratio

Highest at 0.1 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Cyclacel Pharmaceuticals, Inc.

Net Profit

At USD -2.48 MM has Fallen at -54.98%

over average net sales of the previous four periods of USD -1.6 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 8.11 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 77.54% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales